Kenvue Inc. (NYSE:KVUE) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several challenges: weak organic sales growth, distribution issues in Asia Pacific, and economic uncertainties. The lack of a share repurchase program and the operational separation risks add to investor concerns. Despite some positive elements like increased gross margin and brand investment, the overall sentiment is negative due to the financial outlook and management's vague responses during the Q&A. The absence of any strong positive catalysts, such as a new partnership or robust guidance, further supports a negative sentiment.
Key Financial Performance
Adjusted Diluted EPS $0.26, flat year-over-year; inline with expectations.
Organic Sales Growth (Q4 2024) 1.7%, down from expectations; impacted by lower incidences of cough, cold, and flu, and reduced distributor orders in Asia Pacific.
Organic Sales Growth (Full Year 2024) 1.5%, below expectations; primarily due to lower pediatric pain sales and distributor order reductions.
Adjusted Gross Margin 60.4%, up 200 basis points year-over-year; driven by productivity enhancements.
Adjusted Operating Margin (Q4 2024) 19.2%, down from 21.5% for the full year; impacted by increased brand investments.
Total Brand Investment (2024) Increased by about 20% year-over-year; funded by cost savings and gross margin improvements.
Net Interest Expense (Q4 2024) $95 million; in line with expectations.
Adjusted Effective Tax Rate (Q4 2024) 17.7%; slightly below expectations due to discrete tax benefits.
Adjusted Net Income (Q4 2024) $499 million; inline with expectations.
Adjusted Net Income (Full Year 2024) $2.2 billion; within guidance range.
Volume Growth (Q4 2024) 0.7% year-over-year; driven by self-care and skin health segments.
Value Realization (Q4 2024) 1% contribution to organic sales growth; primarily from pricing outside the US.
Organic Sales Growth (Self-Care Q4 2024) 2.9%; strong growth except for pediatric pain.
Organic Sales Growth (Essential Health Q4 2024) -0.7%; impacted by reduced customer orders in Asia Pacific.
Organic Sales Growth (Skin Health and Beauty Q4 2024) 2.6%; volume-led growth in EMEA and Latin America.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: Launched a new major campaign featuring artist Tate McRae as the newest Neutrogena ambassador.
Innovation: Expect to launch 40% more innovation compared to 2024, focusing on premiumization and attractive entry price points.
Market Expansion: Expanded Neutrogena, Aveeno, and OGX in Europe, with Aveeno launching in 12 central European markets.
Consumer Engagement: Increased engagement with consumers and healthcare professionals, particularly in self-care and skin health.
Operational Efficiency: Achieved $350 million of annualized savings by 2026 through a two-year initiative to become a more agile organization.
Cost Management: Expanded adjusted gross margin by 200 basis points year-over-year to 60.4%.
Strategic Shift: Completed approximately 85% of planned exits from transitional service agreements (TSAs) with J&J, enhancing operational independence.
Cultural Shift: Introduced a new performance and incentive model tied to business outcomes, fostering a culture of performance and impact.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Organic Sales Growth: Organic sales growth for 2024 was 1.5%, which was below expectations due to lower incidences of cough, cold, and flu affecting the pediatric pain franchise and a reduction in distributor orders in Asia Pacific, particularly China.
Distribution Network Disruption: There was a temporary disruption in the distribution network for essential health and skin health brands in Asia Pacific, particularly China, due to liquidity issues faced by secondary distributors.
Economic Environment: Entering 2025, Kenvue faces a challenging external environment characterized by economic uncertainty, geopolitical tensions, and a stronger dollar.
Consumer Behavior: Consumers are seeking convenience and value but are not compromising on their health, which may impact sales growth.
Pediatric Pain Franchise: The pediatric pain franchise experienced a significant decline due to a low flu season, impacting overall sales growth.
Destocking and Strategic Investments: In 2025, Kenvue anticipates destocking and strategic investments in price reductions and trade spend in the US to improve competitiveness, which will negatively impact first-half results.
Currency Headwinds: Currency fluctuations are expected to present a 3% headwind to top-line growth in 2025.
Operational Separation Risks: Kenvue is approximately 90 days from completing its operational separation from Johnson & Johnson, which has been resource-intensive and carries risks of business disruption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Adjusted Gross Margin: Expanded adjusted gross margin by 200 basis points year-over-year to 60.4%, driven by strong productivity enhancements.
View Forward Initiative: Executed the first year of a two-year initiative to become a more agile organization, targeting $350 million in annualized savings by 2026.
Brand Investment: Increased total brand investment by about 20% in 2024, focusing on advertising, healthcare professional engagement, and in-store presence.
Innovation Launches: Planned to launch 40% more innovation in 2025 compared to 2024, enhancing portfolio through premiumization and attractive entry price points.
New Operating Model: Activated a new operating model in 2025, enhancing efficiency and accountability across global brand development teams.
Organic Sales Growth 2025: Expect organic sales growth in the range of 2% to 4% for 2025, with volume-led growth.
Revenue Expectations: Expect net sales to range from down 1% to up 1% in 2025, factoring in a 3% currency headwind.
Adjusted Operating Margin: Planning for adjusted operating margin to expand year-over-year in 2025.
Adjusted Diluted EPS: Expect adjusted diluted EPS to be flat to up 2% in 2025, with a mid-single digit headwind from currency.
First Quarter Outlook: Expect organic sales to decline low single digits in Q1 2025 due to destocking and strategic price investments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: Kenvue has not announced any specific share buyback program during this earnings call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give us a sense of the contribution of the drag in Q1, particularly in cold and flu?
A:We expect in the first quarter to have two factors that will depress our results: the low pediatric pain incidents and the lingering impact of distribution disruption in China.
Q:What impact are you expecting from Asia Pacific inventory issues going forward?
A:The lingering impact of the distribution disruption we saw in China will take a little bit of time to fix.
Q:Can you share how you see category growth assumptions playing out in the US versus internationally?
A:We expect our categories to slow down from 3% to 4% to 2% to 3% in 2025, with a lower impact of price compared to 2024.
Q:What are you assuming in the fourth quarter regarding headwinds from weaker cough and cold?
A:We expect a normal season overall in cold, cough, and flu, and the absence of the headwinds we saw in Q4 of 2024.
Q:Can you provide more insight on the innovation pipeline for skin health and beauty?
A:We are going to roll out a much stronger innovation pipeline in 2025 and feel good about the upcoming sun care season.
Q:Can you elaborate on the temporary trade investments you’re embedding in guidance?
A:We are making adjustments to our business to ensure that our brands are at the right price points for consumers.
Q:How should we think about segment margin trajectory, especially in self-care?
A:I would not place too much emphasis on the quarterly margin by segment; it is impacted by mix and is temporary.
Q:What is your expectation for cash flow relative to EPS?
A:We are expecting to get closer to the cash conversion target, but we will not get there in 2025 due to ongoing investments.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the specific timeline and details on fixing the distribution disruptions in Asia Pacific, as well as the exact impact of trade investments on margins.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Asia Pacific
Aveeno OGX
EMEA Latin
Latin America
Neutrogena Aveeno
Pacific China
area
beauty volume
campaign
chapter
communication
competitiveness
customer order
decline pain
digit sale
disruption
distribution
distributor
entry price
factor
flu pain
health beauty
incidence
influencer
issue
model
number face
online
order Asia
pain franchise
prominence
reduction
region
responsibility
self care
skin health
talent
volume sale
KVUE Transcript
Kenvue, Inc. (KVUE) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call reveals several concerning factors: a downward revision of the 2025 outlook, declining sales across segments, supply chain issues, and high SG&A costs. Despite strategic priorities and some brand successes, management's vague responses in the Q&A and lack of concrete guidance further dampen sentiment. The negative financial trends, combined with external pressures like tariffs and competitive challenges, suggest a negative stock price reaction in the short term.
Kenvue Inc. (NYSE:KVUE) Q1 2025 Earnings Call Transcript
Unknown5-9
The earnings call presents mixed signals. While EPS exceeded expectations and there is optimism for the second half of the year, current financial metrics such as declining organic sales and margins pose concerns. The lack of a shareholder return plan and supply chain challenges also weigh negatively. However, the company's innovation and strategic initiatives, along with positive consumer responses, provide a balanced outlook. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction for the next two weeks.
Kenvue, Inc. (KVUE) Q1 2025 Earnings Call Transcript
Unknown5-8
The earnings call reflects a challenging financial situation with declining organic sales, adjusted gross margin, and operating margin. The absence of a share buyback or dividend program further dampens investor sentiment. While management expressed optimism about innovation and growth in the latter half of the year, the lack of specific guidance and clarity in responses, particularly concerning tariff impacts and innovation success tracking, adds uncertainty. The overall sentiment is negative due to these factors, despite some positive consumer response and planned strategic investments.
Kenvue Inc. (NYSE:KVUE) Q4 2024 Earnings Call Transcript
Unknown2-7
The earnings call highlights several challenges: weak organic sales growth, distribution issues in Asia Pacific, and economic uncertainties. The lack of a share repurchase program and the operational separation risks add to investor concerns. Despite some positive elements like increased gross margin and brand investment, the overall sentiment is negative due to the financial outlook and management's vague responses during the Q&A. The absence of any strong positive catalysts, such as a new partnership or robust guidance, further supports a negative sentiment.
KVUE Slides
KVUE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
